Business Context and Reporting Period
This Form 8-K Current Report was filed by Xeris Biopharma Holdings, Inc. on April 21, 2026, regarding events occurring on April 20, 2026. The filing addresses corporate governance changes involving the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Retirement: Dr. Jeffrey Sherman, a director since 2021, notified the Company of his decision to retire and not stand for reelection at the 2026 Annual Meeting of Stockholders.
- Committee Roles: Dr. Sherman served on the Compensation Committee and the Nominating and Corporate Governance Committee. He will continue in these roles until his term expires at the Annual Meeting.
- Board Size Reduction: The Board approved a reduction in its size from eight to seven directors, effective upon the expiration of Dr. Sherman's term.
- Reason for Departure: The filing explicitly states the retirement was not due to any disagreement with the Company or its management regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The document is limited to the announcement of the director's retirement and the resulting structural change to the Board.
Key Facts for Investor Verification
- Confirm the exact date of the 2026 Annual Meeting of Stockholders to determine when the Board size reduction becomes effective.
- Verify if the Company has announced a candidate to fill the vacancy left by Dr. Sherman or if the Board will operate with seven members indefinitely.
- Review the composition of the Compensation and Nominating and Corporate Governance Committees to ensure quorum and compliance with governance guidelines following Dr. Sherman's departure.